• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical investigation >Neuroblastoma drug development: from lab bench to bedside?
【24h】

Neuroblastoma drug development: from lab bench to bedside?

机译：神经母细胞瘤药物开发：从实验室工作台到床边？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Louis Chesler leads the pediatric solid tumor biology and therapeutics team at the Institute of Cancer Research (ICR; London, UK), one of the world's most influential cancer research centers. Previously, Chesler worked for the US Government's National Institute of Health and National Cancer Institute before joining the University of California, San Francisco (CA, USA) in 1995 to run a neuroblastoma research program and works as a paediatric oncology consultant. He moved to the ICR in 2007 as a senior clinical lecturer and is also an honorary consultant at the ICR's partner hospital, the Royal Marsden NHS Foundation Trust. Chesler's current interest is in developing new drugs for childrens' cancers that at present respond poorly to existing treatment. These cancers include the three most common solid tumors of children: neuroblastoma, a nerve tumor; rhabdomyosarcoma, a muscle tumor; and medulloblastoma, a brain tumor. Part of Chesler's work includes investigating the MYCN and ALK genes - which are abnormal in cancers derived from the brain and nervous system - and in developing novel therapeutics targeting these genes, an area of research currently attracting great interest. Chesler is a fellow of the Royal College of Pediatrics and Child Health, American Association for Cancer Research and the American Association of Pediatrics, and is active in several cooperative groups for development of novel cancer drugs, such as the Society of Paediatric Oncology European Neuroblastoma Network, Innovative Therapies for Children with Cancer Consortium, the new agents group of Cancer Research UK, and is on the editorial board for several peer-reviewed journals.
机译：路易斯·切斯勒（Louis Chesler）领导着癌症研究所（ICR;英国伦敦）的儿科实体肿瘤生物学和治疗团队，该研究所是世界上最具影响力的癌症研究中心之一。在此之前，Chesler曾在美国政府的国立卫生研究院和国家癌症研究所工作，然后于1995年加入加利福尼亚大学旧金山分校，负责神经母细胞瘤研究计划，并担任儿科肿瘤学顾问。他于2007年移居ICR，担任高级临床讲师，同时还是ICR合作医院Royal Marsden NHS Foundation Trust的名誉顾问。切斯勒目前的兴趣是开发用于儿童癌症的新药，目前这些新药对现有疗法反应不佳。这些癌症包括儿童的三种最常见的实体瘤：神经母细胞瘤，神经瘤;横纹肌肉瘤，一种肌肉肿瘤;和髓母细胞瘤，一种脑肿瘤。 Chesler的部分工作包括研究MYCN和ALK基因-在源自脑和神经系统的癌症中异常-以及开发针对这些基因的新型疗法，这一领域目前引起了极大的兴趣。切斯勒（Chesler）是英国皇家儿科与儿童健康学院，美国癌症研究协会和美国儿科学会的会员，并且活跃于几个合作组，共同开发新的癌症药物，例如儿科肿瘤学会欧洲神经母细胞瘤网络，癌症研究联合会的新成员，癌症联合会儿童创新疗法，并且是几本经过同行评审的期刊的编辑委员会成员。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号